Ani Pharmaceuticals (ANIP) Cost of Revenue (2012 - 2026)

Ani Pharmaceuticals has disclosed Cost of Revenue across 15 years of filings, most recently posting $100.2 million for Q2 2026.

• In Q2 2026, Cost of Revenue rose 34.23% year-over-year to $100.2 million; the TTM figure through Jun 2026 stood at $387.4 million (up 33.12% YoY), while the FY2025 annual figure was $341.3 million, up 36.41% from the prior year.
• Cost of Revenue came in at $100.2 million for Q2 2026 at Ani Pharmaceuticals, up from $93.6 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $100.3 million in Q4 2025 to a low of $32.9 million in Q3 2022.
• Average Cost of Revenue over 5 years is $61.4 million, with a median of $55.6 million recorded in 2023.
• The largest YoY upside for Cost of Revenue was 71.48% in 2022 against a maximum downside of 7.16% in 2022.
• Over 5 years, Cost of Revenue stood at $36.3 million in 2022, then surged by 47.06% to $53.4 million in 2023, then jumped by 50.28% to $80.3 million in 2024, then advanced by 24.9% to $100.3 million in 2025, then declined by 0.11% to $100.2 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $100.2 million in Q2 2026, $93.6 million in Q1 2026, and $100.3 million in Q4 2025.